Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients with T2DM

Trial Identifier:	D1690L00149
Sponsor:	AstraZeneca
NCTID::	NCT06327815
Start Date:	March 2024
Primary Completion Date:	April 2025
Study Completion Date:	April 2025
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100020
CN	Wei Fang, CN, 261035

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.